98%
921
2 minutes
20
Drug recommendation based on electronic health records (EHR) relies heavily on precise patient modeling, which is more complex than conventional recommendation tasks as it requires both temporal modeling of disease progression and referencing similar patients' medication information. However, sparse visit records and vague patient similarity in EHR data pose significant challenges, often introducing noise and ambiguity. To address the above challenges, we propose RaVSNet (Relevance aware Visit Similarity Network), which improves drug recommendation by leveraging both longitudinal and transversal visit similarity and integrating medical relevance knowledge. RaVSNet utilizes multi-dimensional visit information similar to the patient's current visit as a reference, and employs a relevance-aware network to explicitly model the matching relationships between medical conditions and medications. Additionally, RaVSNet designs a general pretraining framework specifically for drug recommendation, including two tasks, Medication Sequence Reconstruction (MSR) and Causal Effect Inference (CEI), to discover the deep connections between medical information and medications. Experimental results on two public EHR datasets, MIMIC-III and MIMIC-IV demonstrate that the proposed algorithm outperforms state-of-the-art methods, yielding more accurate drug recommendation combinations, and the proposed general pretraining framework can be seamlessly integrated into most drug recommendation methods to achieve performance improvements. The implementation is available at: https://github.com/SCUT-CCNL/RaVSNet.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1109/JBHI.2025.3590391 | DOI Listing |
Clin Transl Sci
September 2025
Food and Drug Administration, Silver Spring, Maryland, USA.
Since the first decentralized clinical trial (DCT) was conducted in 2011, there has been an increased usage of DCT due to its benefits of patient-centricity and generalizability of findings. This trend was further expedited by the global COVID-19 pandemic. We identified 23 case studies across various therapeutic areas and grouped them into different categories according to their purposes-by necessity, for operational benefits, to address unique research questions, to validate innovative digital endpoints, or to validate decentralization as a clinical research platform.
View Article and Find Full Text PDFIndian Pediatr
September 2025
Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
Objective: To determine the cyclosporine trough (C) and two-hour post-dose concentrations (C) in children with nephrotic syndrome (NS) and study the factors influencing them.
Methods: In this ambispective cohort study, children with NS (including frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome) on cyclosporine therapy were enrolled. Clinical and laboratory data were recorded.
Objectives: Cocaine use disorder (CUD) affects 1.4 million people in the United States, yet no FDA-approved treatments exist. In 2023, the Food and Drug Administration (FDA) released a draft guideline on treatments for stimulant use disorders, providing direction for trial design, outcomes, and population selection.
View Article and Find Full Text PDFClin Exp Dent Res
October 2025
Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Objectives: This umbrella meta-analysis aimed to answer the clinical question: Do mini-screws and micro-implants improve specific orthodontic outcomes such as intermolar width, interpremolar width, suture expansion, molar movement, and skeletal width compared to conventional anchorage methods?
Materials And Methods: A systematic search was performed in PubMed, Scopus, ISI Web of Science, and Google Scholar up to October 2024. Systematic reviews and meta-analyses on mini-screws and micro-implants in orthodontic treatment were included. Methodological quality was assessed using AMSTAR 2, and a random-effects model was used to calculate effect sizes (ESs) and 95% confidence intervals (CIs).
Can Commun Dis Rep
August 2025
Division des maladies infectieuses, Centre hospitalier de l'Université de Montréal, Montréal, QC.
Background: In Canada, the burden of gonorrhea has been increasing steadily over the last decade with emerging multi-drug-resistant strains. There is a high genomic similarity between and .
Methods: Review of published studies and on-going trials with the four-component meningococcal serogroup B vaccine (4CMenB-Bexsero®).